With the clear recognition of molecularly defined RCC with papillary growth (e.g., FH-deficient RCC), it can be hypothesized that “type 1” and “type 2” tumors may actually represent progression of “true papillary RCCs from lower to higher grade disease” rather than being different tumor types. This evidence concerns the gene FH and renal cell carcinoma.